3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Dermatologic
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
3
Myelodysplastic Syndromes
2
Pancreatic Neoplasms
1
Mesothelioma, Malignant
1
Melanoma
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
pertuzumab
3
Leucovorin
3
Gemcitabine
3
Fluorouracil
3
trametinib
2
ruxolitinib
2
pembrolizumab
2
palbociclib
2
dabrafenib
2
copanlisib
2
abiraterone
2
Trastuzumab
2
Taxes
2
Sunitinib
2
Specimen Handling
2
Sorafenib
2
Polymerase Chain Reaction
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
Immunoglobulin G
2
HhAntag691
2
Gene Expression Profiling
2
Doxorubicin
2
Disulfides
2
Dasatinib
2
Counseling
2
Carboplatin
2
Bupropion
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
bemcentinib
×
Other hematologic neoplasm
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts